Literature DB >> 19884278

The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders.

Robby Engelmann1, Jan Brandt, Martin Eggert, Kirsten Karberg, Andreas Krause, Gunther Neeck, Brigitte Mueller-Hilke.   

Abstract

OBJECTIVE: Autoantibodies against citrullinated peptide antigens (ACPA) are routinely determined to diagnose rheumatoid arthritis (RA) and are predictive of a more severe course of the disease. We here set out to address an involvement of ACPA in the pathogenesis of RA and investigated the recognition pattern of antibodies against 2 citrullinated antigens in more detail.
METHODS: The sera of 77 patients fulfilling the American College of Rheumatology criteria for RA were analyzed for subclass titers of anti-mutated citrullinated vimentin (MCV) and anticyclic citrullinated peptide (CCP) antibodies by combining subclass specific detection antibodies with commercially available CCP and MCV ELISA plates. Cross-reactivities between anti-MCV and anti-CCP antibodies were detected using a sequential ELISA system.
RESULTS: IgG1, IgG3, and IgG4 titers among anti-MCV and anti-CCP antibodies correlated significantly. Cross-reactivity of MCV-specific antibodies against CCP could be detected in 8 of 16 patients' sera; however, cross-binding of MCV-specific IgG4 was weaker compared to total IgG.
CONCLUSION: The inherent capacity of IgG4 to exchange F(ab) arms provides insight into the anti-MCV antibody diversity and suggests a classification of ACPA positive patients into broad and narrow responders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19884278     DOI: 10.3899/jrheum.081263

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

Review 1.  Antibodies against cyclic citrullinated peptides in infectious diseases--a systematic review.

Authors:  Isabella Lima; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2010-08-05       Impact factor: 2.980

Review 2.  [Antibodies against citrullinated peptides in clinical practice and research].

Authors:  R Engelmann; B Müller-Hilke
Journal:  Z Rheumatol       Date:  2009-08       Impact factor: 1.372

Review 3.  The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis.

Authors:  Katleen Van Steendam; Kelly Tilleman; Dieter Deforce
Journal:  Rheumatology (Oxford)       Date:  2011-01-27       Impact factor: 7.580

4.  Evaluation of autoantibodies against vimentin and α-enolase in rheumatoid arthritis patients.

Authors:  Mina Ebrahimi-Rad; Shohreh Khatami; Hadi Akhbari; Hamid Mahmoudzadeh-Niknam; Shirin Valadbeigi; Mahdi Mahmoudi; Alireza Jamshidi; Farhad Riazi-Rad; Reza Saghiri
Journal:  Reumatologia       Date:  2020-12-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.